Form 4: AbbVie EVP R&D Sells Shares for Tax Obligations
Insider Transaction Report
AbbVie's EVP of R&D and CSO, Roopal Thakkar, reported the disposition of 8,037 shares of common stock to cover tax liabilities.
Summary
- Roopal Thakkar, Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie Inc. (ABBV), reported a transaction.
- On February 27, 2026, 8,037 shares of AbbVie Common Stock, $0.01 par value, were disposed of at a price of $232.08 per share.
- The transaction code 'F' indicates a payment of tax liability by withholding shares.
- Following this transaction, Roopal Thakkar directly beneficially owns 52,376 shares of common stock.
- An indirect beneficial ownership of 2,998 shares in the AbbVie Savings program as of February 20, 2026, was also reported.
- This indirect balance includes shares acquired pursuant to a dividend reinvestment feature and was inadvertently omitted from the Form 3 filed on December 22, 2023.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. The disposition of shares is a routine, non-discretionary transaction to satisfy tax obligations, which is common for executives receiving equity compensation.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance.
Industry Context
StockSavvy.ai notes that routine insider transactions, such as the disposition of shares to cover tax obligations upon vesting of equity awards, are common occurrences across all industries, including the pharmaceutical sector where AbbVie operates. These transactions are typically non-discretionary and do not necessarily reflect management's view on the company's future prospects.
Stakeholder Impact
- Shareholders: The disposition is a routine tax-related event and is unlikely to have a significant impact on shareholder sentiment or the company's valuation.
Key Dates
| Date | Description |
|---|---|
| 12/22/2023 | Date Form 3 was filed, from which certain indirect beneficial ownership was inadvertently omitted. |
| 02/20/2026 | Date as of which the balance in the AbbVie Savings program was calculated for indirect beneficial ownership. |
| 02/27/2026 | Date of the reported transaction (disposition of common stock). |
| 03/03/2026 | Date the Form 4 was signed by the attorney-in-fact for Roopal Thakkar. |
Keywords
AbbVie, ABBV, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Roopal Thakkar, Tax Liability
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.